These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10415878)

  • 1. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.
    Müller P; Jesnowski R; Karle P; Renz R; Saller R; Stein H; Püschel K; von Rombs K; Nizze H; Liebe S; Wagner T; Günzburg WH; Salmons B; Löhr M
    Ann N Y Acad Sci; 1999 Jun; 880():337-51. PubMed ID: 10415878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
    Karle P; Müller P; Renz R; Jesnowski R; Saller R; von Rombs K; Nizze H; Liebe S; Günzburg WH; Salmons B; Löhr M
    Adv Exp Med Biol; 1998; 451():97-106. PubMed ID: 10026857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
    Löhr M; Müller P; Karle P; Stange J; Mitzner S; Jesnowski R; Nizze H; Nebe B; Liebe S; Salmons B; Günzburg WH
    Gene Ther; 1998 Aug; 5(8):1070-8. PubMed ID: 10326030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
    Samel S; Löhr M
    Cancer Treat Res; 2007; 134():469-82. PubMed ID: 17633075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
    Karle P; Renner M; Salmons B; Günzburg WH
    Cancer Gene Ther; 2001 Mar; 8(3):220-30. PubMed ID: 11332993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.
    Samel S; Keese M; Lux A; Jesnowski R; Prosst R; Saller R; Hafner M; Sturm J; Post S; Löhr M
    Cancer Gene Ther; 2006 Jan; 13(1):65-73. PubMed ID: 16096652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century.
    Löhr M; Hummel F; Faulmann G; Ringel J; Saller R; Hain J; Günzburg WH; Salmons B
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S21-4. PubMed ID: 12042985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical protocol for treatment of canine mammary tumors using encapsulated, cytochrome P450 synthesizing cells activating cyclophosphamide: a phase I/II study.
    Winiarczyk S; Gradski Z; Kosztolich B; Gabler C; König G; Renner M; Saller RM; Prosl H; Salmons B; Günzburg WH; Hain J
    J Mol Med (Berl); 2002 Sep; 80(9):610-4. PubMed ID: 12226743
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy.
    Günzburg WH; Karle P; Renz R; Salmons B; Renner M
    Ann N Y Acad Sci; 1999 Jun; 880():326-36. PubMed ID: 10415877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
    Günzburg WH; Salmons B
    Acta Biochim Pol; 2005; 52(3):601-7. PubMed ID: 16175235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small agarose microcapsules with cell-enclosing hollow core for cell therapy: transplantation of Ifosfamide-activating cells to the mice with preestablished subcutaneous tumor.
    Sakai S; Hashimoto I; Tanaka S; Salmons B; Kawakami K
    Cell Transplant; 2009; 18(8):933-9. PubMed ID: 19500478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation.
    Ryschich E; Jesnowski R; Ringel J; Harms W; Fabian OV; Saller R; Schrewe M; Engel A; Schmidt J; Löhr M
    Int J Cancer; 2005 Feb; 113(4):649-53. PubMed ID: 15455374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.
    Salmons B; Löhr M; Günzburg WH
    J Gastroenterol; 2003 Mar; 38 Suppl 15():78-84. PubMed ID: 12698877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors.
    Sakai S; Kawabata K; Tanaka S; Harimoto N; Hashimoto I; Mu C; Salmons B; Ijima H; Kawakami K
    Mol Cancer Ther; 2005 Nov; 4(11):1786-90. PubMed ID: 16276000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
    Kammertoens T; Gelbmann W; Karle P; Alton K; Saller R; Salmons B; Günzburg WH; Uckert W
    Cancer Gene Ther; 2000 Apr; 7(4):629-36. PubMed ID: 10811482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
    Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
    Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
    Jounaidi Y; Chen CS; Veal GJ; Waxman DJ
    Mol Cancer Ther; 2006 Mar; 5(3):541-55. PubMed ID: 16546968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.
    Binder S; Lewis AL; Löhr JM; Keese M
    World J Gastroenterol; 2013 Nov; 19(43):7586-93. PubMed ID: 24282349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.